Stifel analyst David Grossman raised the firm’s price target on Hinge Health (HNGE) to $67 from $59 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNGE:
- Hinge Health Earnings Call Signals Profitable Growth
- Hinge Health Lifts 2026 Outlook After Record Quarter
- Hinge Health Buy Rating Reiterated on Growth Momentum and Migraine Expansion, Price Target Maintained at $72
- Analyst Reiterates Buy on Hinge Health, Citing Near‑Term Outperformance Potential and Long‑Term Growth from New Migraine Care Program
- Hinge Health launching migraine treatment program, WSJ reports